Gilead Sciences, Inc. GILD NASDAQ

Gilead Sciences, Inc. (GILD) reported total assets of $59.02B and total liabilities of $36.41B for fiscal year 2025, resulting in total equity of $22.62B.

The company held $10.61B in cash and short-term investments. Total debt stood at $24.59B, with net debt of $17.03B. The Debt-to-Equity (D/E) ratio was 1.09 (moderate).

Current ratio is 1.68, indicating strong short-term liquidity. Interest coverage is 11.5x (strong).

Criteria supported by this page:

• HEALTH (83/100, Pass) — Debt-to-Equity of 1.09, current ratio of 1.68, interest coverage 11.5x — balance sheet is strong
• MOAT (90/100) — Total assets $59.02B and equity $22.62B support the company's competitive scale
• VALUE (57/100) — Debt-to-Equity 1.09 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 78/100 with 6/7 criteria passed.

LLY

Eli Lilly and Company

$922.50

-0.76%

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%

AZN

AstraZeneca PLC

$204.38

+1.06%

MRK

Merck & Co., Inc.

$119.96

-0.16%

AMGN

Amgen Inc.

$350.95

+0.32%

PFE

Pfizer Inc.

$27.13

-0.77%

BMY

Bristol-Myers Squibb Company

$58.08

+0.03%